Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Amphotericin B
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Antifungal === One of the main uses of amphotericin B is treating a wide range of systemic [[Fungal infection in animals|fungal infection]]s. Due to its extensive side effects, it is often reserved for severe infections in critically ill or [[immunocompromised]] patients. It is considered first line therapy for invasive [[mucormycosis]] infections, [[Cryptococcosis|cryptococcal meningitis]], and certain [[Aspergillosis|aspergillus]] and [[Candidiasis|candidal]] infections.<ref>{{cite book|title = Drugs Active against Fungi, Pneumocystis, and Microsporidia|isbn = 978-1-4557-4801-3|pages = 479β494.e4| vauthors = Bennett JE, Dolin R, Blaser MJ |date = 28 August 2014| publisher=Elsevier Health Sciences }}</ref><ref>{{cite journal | vauthors = Moen MD, Lyseng-Williamson KA, Scott LJ | title = Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections | journal = Drugs | volume = 69 | issue = 3 | pages = 361β392 | date = 2012-09-17 | pmid = 19275278 | doi = 10.2165/00003495-200969030-00010 | s2cid = 34340503 }}</ref> It has been a highly effective drug for over fifty years in large part because it has a low incidence of [[Antimicrobial resistance|drug resistance]] in the pathogens it treats. This is because amphotericin B resistance requires sacrifices on the part of the pathogen that make it susceptible to the host environment, and too weak to cause infection.<ref>{{cite news|url=http://wi.mit.edu/news/archive/2013/understanding-evolution-drug-resistance-points-novel-strategy-developing-better|title=Understanding the evolution of drug resistance points to novel strategy for developing better antimicrobials| vauthors = Rura N |date=2013-10-29|access-date=2016-11-14|via=Whitehead Institute|url-status=live|archive-url=https://web.archive.org/web/20161115134239/http://wi.mit.edu/news/archive/2013/understanding-evolution-drug-resistance-points-novel-strategy-developing-better|archive-date=2016-11-15}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)